For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| Research and development | 1,376,861 | 1,295,286* | 922,857 | |
| General and administrative | 1,715,639 | 1,946,495* | 1,020,154 | |
| Total operating expenses | 3,092,500 | 3,241,781 | 1,943,011 | |
| Loss from operations | -3,092,500 | -3,241,781* | -1,943,011 | |
| Change in fair value of warrant liability | - | -325* | -611 | |
| Other income (expense), net | 83,449 | 49,335* | 35,224 | |
| Total other income (expense), net | 83,449 | 49,660* | 35,835 | |
| Net loss | -3,009,051 | -3,192,121* | -1,907,176 | |
| Deemed dividends | 5,681,616 | -2,357,698* | 2,769,742 | |
| Net loss attributable to common stockholders | -8,690,667 | -834,423 | -4,676,918 | |
| Basic EPS | -2.71 | 0.595 | -1.77 | |
| Diluted EPS | -2.71 | 0.595 | -1.77 | |
| Basic Average Shares | 3,207,720 | -1,403,163 | 2,644,733 | |
| Diluted Average Shares | 3,207,720 | -1,403,163 | 2,644,733 | |
REVELATION BIOSCIENCES, INC. (REVB)
REVELATION BIOSCIENCES, INC. (REVB)